Clinical Trial

A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study compares the efficacy and safety of AK104 versus Sugemalimab as consolidation therapy in patients with unresectable, locally advanced NSCLC who have not progressed following concurrent or sequential chemoradiotherapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-09-25.
Status change: Not Yet Recruiting → Recruiting 2025-03-11
Trial Details
NCT Number NCT06617416
Lead Sponsor Akeso
Conditions NSCLC (Non-small Cell Lung Cancer)
Enrollment 560 participants
Start Date 2024-11-12
Primary Completion 2026-10-28 (estimated)
Study Completion 2028-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-03-12